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PURPOSE. To determine whether mitochondrial DNA haplogroups or rare variants associate
with primary open-angle glaucoma in subjects of European descent.
METHODS. A case–control comparison of age- and sex-matched cohorts of 90 primary open-
angle glaucoma patients and 95 population controls. Full mitochondrial DNA sequences from
peripheral blood were generated by next-generation sequencing and compared to the revised
Cambridge Reference Sequence to define mitochondrial haplogroups and variants.
RESULTS. Most subjects were of the major European haplogroups H, J, K, U, and T. Logistic
regression analysis showed haplogroup U to be significantly underrepresented in male
primary open-angle glaucoma subjects (odds ratio 0.25; 95% confidence interval [CI] 0.09–
0.67; P ¼ 0.007; Bonferroni multiple testing P ¼ 0.022). Variants in the mitochondrial DNA
gene MT-ND2 were overrepresented in the control group (P ¼ 0.005; Bonferroni multiple
testing correction P ¼ 0.015).
CONCLUSIONS. Mitochondrial DNA ancestral lineages modulate the risk for primary open-angle
glaucoma in populations of European descent. Haplogroup U and rare variants in the
mitochondrial DNA-encoded MT-ND2 gene may be protective against primary open-angle
glaucoma. Larger studies are warranted to explore haplogroup associations with disease risk
in different ethnic groups and define biomarkers of primary open-angle glaucoma
endophenotypes to target therapeutic strategies.
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Primary open-angle glaucoma (POAG) is a heterogenousdisease grouping associated with selective loss of retinal
ganglion cells and is a leading cause of blindness worldwide.
POAG is often associated with increased intraocular pressure
(IOP), but many cases progress despite IOP being within
normal ranges.1 The specificity of retinal ganglion cell loss in
POAG resembles mitochondrial optic neuropathies, which are
rare diseases caused by genetic defects in either nuclear-
encoded mitochondrial genes or mitochondrial DNA (mtDNA)
genes.2 In both these disease groupings retinal ganglion cells
are lost in the absence of other central nervous system
pathology. The pattern of axonal loss in the optic nerve can
be distinct, however, with preferential loss of smaller-caliber
parvocellular axons in mitochondrial optic neuropathies
leading to central scotomas, while in POAG larger-caliber
magnocellular fibers tend to be preferentially affected leading
to more arcuate field defects.3,4 POAG fiber loss can vary from
this classic pattern, with many cases involving central field
defects,5 possibly reflecting the heterogenous nature of the
disease group. The broad similarities of optic nerve degener-
ation in mitochondrial optic neuropathies and POAG have been
long noted, driving interest in studying mitochondrial function
and mtDNA variation in POAG.6–8 Studies using peripheral
blood-derived lymphoblast cell lines have reported evidence of
oxidative phosphorylation (OXPHOS) complex I defects in
POAG.9,10 Further exploration of mitochondrial function and
genetics in POAG may lead to markers of a subtype with a
mitochondrial etiology.
An increased incidence of POAG among patients’ first-
degree relatives is well established; relatives of POAG patients
have a 22% risk of developing POAG at some point in their lives,
whereas the risk for the relatives of controls is 2% to 3%.11 This
risk has been shown to be two to five times greater on the
maternal side of families.12 However, only two genes, myocilin
(MYOC) and optineurin (OPTN), have been established to cause
familial POAG with high penetrance. Myocilin mutations
account for 2% to 4% of POAG and are associated with high
IOP, while optineurin mutations may account for 1% of POAG
and 2% of normal-tension glaucoma.11 MtDNA variation has
been hypothesized to be involved in POAG risk, with studies
suggesting increased levels of rare mtDNA variants in POAG
cases.13,14 While interesting findings are emerging, systematic
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studies to date have not always considered the population
structure of mtDNA ancestry in their analyses. MtDNA is
exclusively maternally inherited, and several ancient single
nucleotide variants (SNVs) are inherited as a group, termed a
haplogroup. MtDNA haplogroups represent human popula-
tions having the same ancestral origins and migration patterns
and have been associated with disease risk.15,16 Here, we
investigated the potential association between mtDNA hap-
logroups and rare mtDNA variants in POAG in a clinically
defined cohort of patients and population controls of European
descent.
METHODS
Participants
Inclusion criteria for the study were as follows: evidence of
glaucomatous optic neuropathy identified by loss of the
neuroretinal rim and retinal nerve fiber layer loss, and
corresponding visual field defect and open angles on
gonioscopy. All patients and population controls underwent
a detailed medical history and slit-lamp biomicroscopy as
well as blood sampling for lymphocyte DNA isolation. The
IOP was measured by Goldmann applanation tonometry and
all assessments were performed at 3 PM 6 1 hour. All
patients were receiving treatment for POAG at the time of
recruitment. Subjects with congenital angle-closure glauco-
ma, trauma-associated secondary glaucoma, or neovascular
glaucoma were excluded. The study adhered to the tenets of
the Declaration of Helsinki; institutional human ethics
committee (Royal Victorian Eye and Ear Hospital) approval
was granted, and written informed consent was acquired
from all patients.
Data Acquisition and Sequencing
MtDNA sequencing was undertaken by the Australian
Genome Research Facility using the Illumina HiSeq platform
(Illumina, Inc., San Diego, CA, USA). From 100 ng total DNA
per sample, entire mtDNAs were amplified in two overlap-
ping fragments with PCR primers known to avoid nuclear
mtDNA pseudogene (NUMT) sequences.17 The PCR frag-
ments were combined in equal ratios, and PCR amplicons
enzymatically fragmented using NEBNext dsDNA Fragmen-
tase (New England Biolabs, Ipswich, MA, USA). Illumina-
compatible NEXTflex PCRfree 48-plex barcode oligonucleo-
tide adapters (Bio Scientific, Sydney, New South Wales,
Australia) were then ligated. Following size selection on a 2%
agarose gel, the cluster formation and sequencing by
synthesis were performed using an Illumina HiSeq2000
instrument, 101-bp (base pair) paired-end reads, and V3
reagents according to the manufacturer’s protocols (Illumina,
Inc.). Average read depth achieved was 10,000.
Since mtDNA is exclusively maternally inherited, there is no
recombination and many mtDNA variants are in high linkage
disequilibrium (LD), that is, occur on the same DNA molecule.
Indeed, this fact leads to the presence of mitochondrial
haplogroups. The majority of mtDNA-encoded genes are
involved in the electron transport chain, and hence it is likely
that these mtDNA variants are in high LD to allow coevolution
of the various components of the electron transport chain to
adapt to different environments and conditions. Due to this
high LD in mtDNA, to avoid errors in statistical computations,
we computed representative tag SNVs for variant association
analysis with POAG, and all single variant analyses were
computed using these tag SNVs.
Sequencing Analysis
Paired-end sequence reads in fastq files were aligned with bwa
mem version 0.7.1518 using default alignments to the revised
Cambridge Reference Sequence (rCRS - NC_012920.1). Dupli-
cate reads were identified using Picard tools version 1.130
(http://broadinstitute.github.io/picard; in the public domain).
Variants were called using freebayes, a haplotype-based variant
detector version 1.1.019 with arguments ‘‘-p 1 –C 2 –q 10.’’
Using homoplasmic mtDNA variant calls only, haplogroups
were then inferred using Haplogrep software version 2.1.0.20
To avoid errors in statistical computations, we computed
representative tag SNVs for variant association analysis with
POAG, and all single variant analyses were computed using
these tag SNVs. Tag SNVs were computed from 30,589 full
mtDNA sequences from mitomap (http://www.mitomap.org;
in the public domain), using PLINK 2.0 (http://www.cog-ge
nomics.org/plink/2.0/; in the public domain), and Lewontin’s
D’ statistic as a measure of LD.
Statistical Analysis
All statistical analyses were performed using R version 3.2.1 (R
Foundation, Vienna, Austria). All P values were reported after
Bonferroni multiple testing correction, where applicable.
Burden tests were performed with the adaptive sum of
powered scores (aSPU) tests,21 using 20,000 permutations.
RESULTS
Male Individuals in Mitochondrial Haplogroup U
Have a Lower Risk for POAG
Mitochondrial haplogroups for 90 POAG patients and 95
population controls in this study were inferred from homo-
plasmic mtDNA. The haplogroup distribution we obtained
showed a predominantly Western European maternal ancestry
of our study population, which was closely matched between
cases and controls. This reflects the older demographic
sampled in Australia. Due to the small numbers of individuals
in some haplogroups, we combined haplogroups according to
the mtDNA phylogenetic tree (phylotree build 17).22 Demo-
graphic and haplogroup information for this study cohort is
included in Supplementary Table S1. To determine if the
haplogroup of an individual is a significant predictor for POAG,
we used logistic regression analysis with the POAG status of
the individual as the response variable, while adjusting for age.
We defined haplogroup RU as the European root macro-
haplogroup R (including haplogroups B, F, H, HV, J, R, T, V)
minus haplogroup U. We disregarded haplogroup L because
there was only one person from this group in our study. We
found that men in haplogroup U were at approximately four
times lower risk for POAG compared to men in haplogroup RU
(Table 1). In our study, there was no association between
POAG risk and mtDNA haplogroup in the cases when both
sexes were combined (Supplementary Table S2).
Rare mtDNA SNVs Are Associated With POAG
To avoid private mutations, a rare mtDNA variant was defined
as a variant that was not common (see below) and was present
in at least three people. There were 133 unique mtDNA rare
variants detected in the data set. We aggregated rare variants
within mtDNA genes to increase statistical power and applied
the genetic burden aSPU tests implemented in the aSPU R
package.21 We also restricted analysis to genes having at least
25 nonreference variants, which resulted in two genes and the
noncoding regulatory D-Loop region. We found that individuals
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having rare variants in the MT-ND2 gene were at significantly
lower risk for POAG than individuals without these variants
(Table 2).
We defined common mtDNA SNVs as those variants having
a minor allele frequency of at least 15%, which yielded nine
unique common variants (Supplementary Table S3). To
determine if common mtDNA SNVs were associated with
POAG, we performed logistic regression analysis with disease
status as the response variable and age, sex, and common
variants as covariates. None of the common mtDNA variants
were significantly associated with POAG after multiple testing
correction at the 0.05 level.
DISCUSSION
Several studies have investigated mtDNA variation in POAG,
but few have used a phylogenetic approach to consider
variants either inherited as a group (haplogroups) or the
genetic burden of multiple rare mtDNA variants, as we report
here. Some earlier reports have led to spurious conclusions
due to a lack of consideration of mitochondrial haplogroups.
Abu-Amero et al.23 sequenced the entire mtDNA of 27 Arabic
POAG patients, finding 34 nonsynonymous sequence variants
not detected in 159 population controls. However, when the
same group later considered haplogroups in an expanded
population sample, they found that African haplogroups were
enriched in their case group, accounting for the increased
levels of variants in their POAG cohort.24
Other studies have not considered mtDNA haplogroups.
Banerjee et al.13 sequenced entire mtDNAs from 101 Indian
POAG patients and 71 controls. The authors also found
significantly increased nonsynonymous SNVs in mtDNA of
POAG patients, particularly in complex I genes, and suggested
the MT-ND5 gene as a mutation ‘‘hot spot’’ in POAG. Most of
their patients and controls belonged to haplogroup M, which
predominates in the Indian subcontinent. Yet their patient
group included 18 individuals of the European root haplogroup
R while their control group included only 5 haplogroup R
individuals. Such disparities lead to apparent differences in
levels of variants seen. In their list of rare variants found only in
POAG cases, the variant m.5178C>A is a defining SNV for
haplogroup D; the variant m.9055G>A is a defining SNV for
haplogroup K; the variant m.14000T>A is commonly associ-
ated with haplogroup L1c (Table 3 in Banerjee et al.13). Thus
three out of four ‘‘rare variants’’ that were recorded multiple
times are explained by rare haplogroups in their population.
Another study of 32 POAG subject mtDNAs found higher levels
of rare variants in cases compared with controls.14 Half of the
cases in this study were from the United Kingdom and half
from India. The authors state that 110 ‘‘ethnically matched’’
controls were also sequenced, but no mtDNA haplogroups
were reported for their cases or controls. Their table of rare
variants also shows haplogroup marker SNVs. The variant
m.1453A>G (two patients) is a defining SNV of haplogroup
M2; variant m.3866T>C (two patients) is found on haplogroup
J; variant m.4336T>C (one patient) is found on haplogroup
M5; variant m.12397A>G (two patients) is found on hap-
logroup M19.14 This finding shows the need to first consider
haplogroup associations, and then sort rare variants that
conflict with the patient haplogroup, as we have done.
Common pitfalls in mtDNA disease association studies have
been critically reviewed elsewhere.25
TABLE 1. Men in Haplogroup U Are Underrepresented in POAG
Predictor M N U Intercept Age
Total number (%) 5 (5.2) 10 (10.3) 24 (24.7) N/A 97 (100)
POAG patients (%) 4 (7.7) 4 (7.7) 7 (13.4) N/A 52 (53.6)
Odds ratio (95% confidence interval) 2.31 (0.31–46.8) 0.37 (0.09–1.47) 0.23 (0.08–0.63) 0.55 (0.04–5.77) 1.02 (0.98–1.06)
P value 0.468 0.164 0.005 0.619 0.325
P value, Bonferroni correction 1.000 0.492 0.016 0.619 0.325
Logistic regression analysis results for male individuals only with POAG status as response variable. RU was chosen as the reference haplogroup.
Multiple testing correction was performed on haplogroup predictors. Each column represents a predictor (either a haplogroup or intercept or age),
and each row represents an attribute; thus each cell represents the value of an attribute for a given predictor. Haplogroup L comprised one male
patient with POAG and was removed from the analysis. N/A, not applicable.
TABLE 2. aSPU Analysis of Rare mtDNA Variants Detected
Gene or
Genetic Region SNV
Total
No. (%)
POAG
(%)
T
Statistic
P
Value
P Value,
Bonferroni
Correction
MT-ND2 m.4646T>C, m.4688T>C, m.4727A>G,
m.4732A>G, m.4833A>G, m.4960C>T,
m.5108T>C, m.5432A>G, m.5480A>G,
m.5495T>C
29 (15.7) 9 (31.0) 0.001 0.003 0.008
D Loop m.72T>C, m.119T>C, m.131T>C, m.159T>C,
m.321T>C, m.444A>G, m.462C>T, m.471T>C,
m.482T>C, m.497C>T, m.16051A>G,
m.16111C>T, m.16144T>A, m.16162A>G,
m.16163A>G, m.16213G>A, m.16214C>T,
m.16218C>T, m.16219A>G, m.16220A>C,
m.16223C>T, m.16224T>C, m.16248C>T,
m.16249T>C, m.16301C>T, m.16399A>G
88 (47.5) 42 (47.7) 0.361 0.643 1.000
rRNA m.723A>C, m.980T>C, m.1189T>C, m.1284T>C,
m.1391T>C, m.1721C>T, m.2217C>T,
m.2639C>T, m.2835C>A, m.3197T>C
36 (19.5) 16 (44.4) 0.401 0.641 1.000
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Another group has focused on African American POAG
patients, initially reporting no differences in rare variant levels
between cases and controls.26 This group then used a mtDNA
haplogroup approach, finding African haplogroups L1c2,
L1c2b, and L2 significantly enriched in their cases.27 Our
analyses in a population of predominantly Western European
ancestry showed some surprising associations for the relatively
small sample size. We found that individuals in haplogroup U
were significantly underrepresented in male POAG cases,
suggesting a protective effect of these lineages for males only. A
study of German glaucoma patients found haplogroup U
significantly underrepresented in pseudoexfoliation glaucoma
subjects, and a trend for haplogroup U being underrepresented
in POAG; however, they did not investigate sex as a variable.28
A second finding in our study was a significantly lower
frequency of rare variants in the MT-ND2 gene in cases
compared with controls, suggesting a protective effect against
POAG. This finding predicts that subsets of several common
variants may be required for glaucoma to progress. Complex
age-related diseases such as glaucoma are likely to have
environmental risk factors in addition to genetic risk factors,
and different mtDNA haplogroups or rare variants may act as
risk or protective ‘‘alleles’’ depending on the environment and
cellular dependence on OXPHOS.29 In vitro studies have
shown that human mtDNA haplogroups show differences in
OXPHOS capacity.30,31
Studies in much larger cohorts of POAG and ophthalmo-
logically screened population controls are warranted to further
test for mtDNA influence on disease risk. Importantly, as POAG
is a heterogeneous disease grouping, the role of mtDNA
variation in patients stratified by normal-tension glaucoma,
slightly elevated IOP, high IOP, progression rates, or visual field
loss patterns requires further investigation. Our findings imply
that disease risk variants in mtDNA will be uncovered in larger
studies and may lead to identification of mtDNA biomarkers
that define a POAG endophenotype of mitochondrial origin.
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